Hayward, Calif.
Went public 10/5/00 at $14 per share
Shares Outstanding:23.8 million shares
Underwriters: Lehman Brothers/CIBC World Markets/SG Cowen Securities/Fidelity Capital Markets
Company Counsel: Wilson Sonsini Goodrich & Rosati
Manager Counsel: Brobeck Phleger & Harrison LLP
Auditor: Ernst & Young LLP
The Company:
Develops new pharmaceuticals through the application of “combinatorial biosynthesis”, the generation of novel analogs of natural products by genetic engineering of biosynthetic pathways.
Venture Backers:
Alta Partners
EuclidSR Partners
Sofinnova Ventures
Walden International Investment Group
Goldman, Sachs & Co.
Burr, Egan, Deleage & Co.
Financing Rounds:
Number of Round Amt.
Round # Round Date Stage Investors ($ thousands)
1 04/01/1996 2 Expansion 3000.0
2 01/03/1997 5 Early Stage 2399.9
3 04/02/1998 8 Expansion 15000.1
4 03/24/2000 8 Expansion 24930.0
Financials:
(Data in $ millions)
Y/E
12/31/99
Total Revenues: $5.3
Net Income: -4.4